nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—PTK6—uterine cervix—fallopian tube cancer	0.0162	0.0162	CbGeAlD
Vandetanib—LTK—female reproductive system—fallopian tube cancer	0.0126	0.0126	CbGeAlD
Vandetanib—BMPR1B—epithelium—fallopian tube cancer	0.0124	0.0124	CbGeAlD
Vandetanib—PTK6—female reproductive system—fallopian tube cancer	0.0121	0.0121	CbGeAlD
Vandetanib—PTK6—female gonad—fallopian tube cancer	0.011	0.011	CbGeAlD
Vandetanib—PTK6—vagina—fallopian tube cancer	0.011	0.011	CbGeAlD
Vandetanib—BMPR1B—uterus—fallopian tube cancer	0.0102	0.0102	CbGeAlD
Vandetanib—EPHA6—female reproductive system—fallopian tube cancer	0.0101	0.0101	CbGeAlD
Vandetanib—PLK4—female reproductive system—fallopian tube cancer	0.00999	0.00999	CbGeAlD
Vandetanib—EGFR—uterine cervix—fallopian tube cancer	0.00992	0.00992	CbGeAlD
Vandetanib—FLT4—epithelium—fallopian tube cancer	0.00975	0.00975	CbGeAlD
Vandetanib—RIPK2—epithelium—fallopian tube cancer	0.0097	0.0097	CbGeAlD
Vandetanib—RIPK2—uterine cervix—fallopian tube cancer	0.00962	0.00962	CbGeAlD
Vandetanib—VEGFA—uterine cervix—fallopian tube cancer	0.00959	0.00959	CbGeAlD
Vandetanib—FMO1—uterine cervix—fallopian tube cancer	0.00954	0.00954	CbGeAlD
Vandetanib—IRAK4—uterine cervix—fallopian tube cancer	0.00939	0.00939	CbGeAlD
Vandetanib—TYRO3—female reproductive system—fallopian tube cancer	0.00938	0.00938	CbGeAlD
Vandetanib—ERBB3—epithelium—fallopian tube cancer	0.00928	0.00928	CbGeAlD
Vandetanib—ERBB3—uterine cervix—fallopian tube cancer	0.0092	0.0092	CbGeAlD
Vandetanib—BMPR1B—female reproductive system—fallopian tube cancer	0.00919	0.00919	CbGeAlD
Vandetanib—MAP3K19—female reproductive system—fallopian tube cancer	0.00919	0.00919	CbGeAlD
Vandetanib—RIPK2—endometrium—fallopian tube cancer	0.0087	0.0087	CbGeAlD
Vandetanib—VEGFA—endometrium—fallopian tube cancer	0.00867	0.00867	CbGeAlD
Vandetanib—MKNK1—uterine cervix—fallopian tube cancer	0.00864	0.00864	CbGeAlD
Vandetanib—FMO1—endometrium—fallopian tube cancer	0.00863	0.00863	CbGeAlD
Vandetanib—RET—epithelium—fallopian tube cancer	0.00861	0.00861	CbGeAlD
Vandetanib—LCK—uterine cervix—fallopian tube cancer	0.00854	0.00854	CbGeAlD
Vandetanib—TYRO3—female gonad—fallopian tube cancer	0.00854	0.00854	CbGeAlD
Vandetanib—AXL—uterine cervix—fallopian tube cancer	0.0085	0.0085	CbGeAlD
Vandetanib—IRAK4—endometrium—fallopian tube cancer	0.00849	0.00849	CbGeAlD
Vandetanib—EPHA5—vagina—fallopian tube cancer	0.00848	0.00848	CbGeAlD
Vandetanib—BMPR1B—female gonad—fallopian tube cancer	0.00836	0.00836	CbGeAlD
Vandetanib—EGFR—uterus—fallopian tube cancer	0.00827	0.00827	CbGeAlD
Vandetanib—SLK—uterine cervix—fallopian tube cancer	0.00818	0.00818	CbGeAlD
Vandetanib—VEGFA—uterus—fallopian tube cancer	0.00799	0.00799	CbGeAlD
Vandetanib—FLT3—female reproductive system—fallopian tube cancer	0.00798	0.00798	CbGeAlD
Vandetanib—FYN—uterine cervix—fallopian tube cancer	0.00796	0.00796	CbGeAlD
Vandetanib—TEK—epithelium—fallopian tube cancer	0.00784	0.00784	CbGeAlD
Vandetanib—MKNK1—endometrium—fallopian tube cancer	0.00782	0.00782	CbGeAlD
Vandetanib—STK35—female reproductive system—fallopian tube cancer	0.00781	0.00781	CbGeAlD
Vandetanib—MAP4K5—uterine cervix—fallopian tube cancer	0.00778	0.00778	CbGeAlD
Vandetanib—FGR—endometrium—fallopian tube cancer	0.00772	0.00772	CbGeAlD
Vandetanib—AXL—endometrium—fallopian tube cancer	0.00769	0.00769	CbGeAlD
Vandetanib—ERBB3—uterus—fallopian tube cancer	0.00767	0.00767	CbGeAlD
Vandetanib—EPHB6—uterine cervix—fallopian tube cancer	0.00743	0.00743	CbGeAlD
Vandetanib—SLK—endometrium—fallopian tube cancer	0.0074	0.0074	CbGeAlD
Vandetanib—FLT3—female gonad—fallopian tube cancer	0.00726	0.00726	CbGeAlD
Vandetanib—FLT4—female reproductive system—fallopian tube cancer	0.00724	0.00724	CbGeAlD
Vandetanib—RIPK2—female reproductive system—fallopian tube cancer	0.0072	0.0072	CbGeAlD
Vandetanib—FYN—endometrium—fallopian tube cancer	0.0072	0.0072	CbGeAlD
Vandetanib—YES1—uterine cervix—fallopian tube cancer	0.00718	0.00718	CbGeAlD
Vandetanib—STK10—uterine cervix—fallopian tube cancer	0.00712	0.00712	CbGeAlD
Vandetanib—LCK—uterus—fallopian tube cancer	0.00711	0.00711	CbGeAlD
Vandetanib—STK35—female gonad—fallopian tube cancer	0.00711	0.00711	CbGeAlD
Vandetanib—AXL—uterus—fallopian tube cancer	0.00709	0.00709	CbGeAlD
Vandetanib—STK35—vagina—fallopian tube cancer	0.00707	0.00707	CbGeAlD
Vandetanib—TEK—endometrium—fallopian tube cancer	0.00703	0.00703	CbGeAlD
Vandetanib—MAP4K5—endometrium—fallopian tube cancer	0.00703	0.00703	CbGeAlD
Vandetanib—SRC—epithelium—fallopian tube cancer	0.00697	0.00697	CbGeAlD
Vandetanib—ABL2—female gonad—fallopian tube cancer	0.00693	0.00693	CbGeAlD
Vandetanib—SRC—uterine cervix—fallopian tube cancer	0.00691	0.00691	CbGeAlD
Vandetanib—ERBB3—female reproductive system—fallopian tube cancer	0.0069	0.0069	CbGeAlD
Vandetanib—ABL2—vagina—fallopian tube cancer	0.00689	0.00689	CbGeAlD
Vandetanib—SLK—uterus—fallopian tube cancer	0.00682	0.00682	CbGeAlD
Vandetanib—EGFR—female gonad—fallopian tube cancer	0.00676	0.00676	CbGeAlD
Vandetanib—EPHB6—endometrium—fallopian tube cancer	0.00672	0.00672	CbGeAlD
Vandetanib—FYN—uterus—fallopian tube cancer	0.00663	0.00663	CbGeAlD
Vandetanib—FLT4—female gonad—fallopian tube cancer	0.00659	0.00659	CbGeAlD
Vandetanib—RIPK2—female gonad—fallopian tube cancer	0.00656	0.00656	CbGeAlD
Vandetanib—VEGFA—female gonad—fallopian tube cancer	0.00654	0.00654	CbGeAlD
Vandetanib—RIPK2—vagina—fallopian tube cancer	0.00652	0.00652	CbGeAlD
Vandetanib—FMO1—female gonad—fallopian tube cancer	0.0065	0.0065	CbGeAlD
Vandetanib—VEGFA—vagina—fallopian tube cancer	0.0065	0.0065	CbGeAlD
Vandetanib—YES1—endometrium—fallopian tube cancer	0.0065	0.0065	CbGeAlD
Vandetanib—TEK—uterus—fallopian tube cancer	0.00648	0.00648	CbGeAlD
Vandetanib—MAP4K5—uterus—fallopian tube cancer	0.00648	0.00648	CbGeAlD
Vandetanib—MKNK1—female reproductive system—fallopian tube cancer	0.00647	0.00647	CbGeAlD
Vandetanib—FMO1—vagina—fallopian tube cancer	0.00646	0.00646	CbGeAlD
Vandetanib—KDR—epithelium—fallopian tube cancer	0.00641	0.00641	CbGeAlD
Vandetanib—IRAK4—female gonad—fallopian tube cancer	0.0064	0.0064	CbGeAlD
Vandetanib—FGR—female reproductive system—fallopian tube cancer	0.0064	0.0064	CbGeAlD
Vandetanib—AXL—female reproductive system—fallopian tube cancer	0.00637	0.00637	CbGeAlD
Vandetanib—IRAK4—vagina—fallopian tube cancer	0.00636	0.00636	CbGeAlD
Vandetanib—MAP2K5—uterine cervix—fallopian tube cancer	0.00636	0.00636	CbGeAlD
Vandetanib—KDR—uterine cervix—fallopian tube cancer	0.00636	0.00636	CbGeAlD
Vandetanib—ERBB3—female gonad—fallopian tube cancer	0.00628	0.00628	CbGeAlD
Vandetanib—YES1—uterus—fallopian tube cancer	0.00599	0.00599	CbGeAlD
Vandetanib—FYN—female reproductive system—fallopian tube cancer	0.00596	0.00596	CbGeAlD
Vandetanib—STK10—uterus—fallopian tube cancer	0.00593	0.00593	CbGeAlD
Vandetanib—MKNK1—female gonad—fallopian tube cancer	0.00589	0.00589	CbGeAlD
Vandetanib—MKNK1—vagina—fallopian tube cancer	0.00586	0.00586	CbGeAlD
Vandetanib—MAP4K5—female reproductive system—fallopian tube cancer	0.00583	0.00583	CbGeAlD
Vandetanib—TEK—female reproductive system—fallopian tube cancer	0.00583	0.00583	CbGeAlD
Vandetanib—LCK—female gonad—fallopian tube cancer	0.00582	0.00582	CbGeAlD
Vandetanib—FGR—female gonad—fallopian tube cancer	0.00582	0.00582	CbGeAlD
Vandetanib—AXL—female gonad—fallopian tube cancer	0.0058	0.0058	CbGeAlD
Vandetanib—LCK—vagina—fallopian tube cancer	0.00578	0.00578	CbGeAlD
Vandetanib—FGR—vagina—fallopian tube cancer	0.00578	0.00578	CbGeAlD
Vandetanib—AXL—vagina—fallopian tube cancer	0.00576	0.00576	CbGeAlD
Vandetanib—KDR—endometrium—fallopian tube cancer	0.00575	0.00575	CbGeAlD
Vandetanib—MAP2K5—endometrium—fallopian tube cancer	0.00575	0.00575	CbGeAlD
Vandetanib—FMO3—vagina—fallopian tube cancer	0.00559	0.00559	CbGeAlD
Vandetanib—SLK—female gonad—fallopian tube cancer	0.00558	0.00558	CbGeAlD
Vandetanib—PDGFRB—epithelium—fallopian tube cancer	0.00555	0.00555	CbGeAlD
Vandetanib—SLK—vagina—fallopian tube cancer	0.00555	0.00555	CbGeAlD
Vandetanib—PDGFRB—uterine cervix—fallopian tube cancer	0.0055	0.0055	CbGeAlD
Vandetanib—FYN—female gonad—fallopian tube cancer	0.00542	0.00542	CbGeAlD
Vandetanib—FYN—vagina—fallopian tube cancer	0.00539	0.00539	CbGeAlD
Vandetanib—YES1—female reproductive system—fallopian tube cancer	0.00538	0.00538	CbGeAlD
Vandetanib—STK10—female reproductive system—fallopian tube cancer	0.00533	0.00533	CbGeAlD
Vandetanib—TEK—female gonad—fallopian tube cancer	0.0053	0.0053	CbGeAlD
Vandetanib—MAP4K5—female gonad—fallopian tube cancer	0.0053	0.0053	CbGeAlD
Vandetanib—KDR—uterus—fallopian tube cancer	0.0053	0.0053	CbGeAlD
Vandetanib—MAP4K5—vagina—fallopian tube cancer	0.00527	0.00527	CbGeAlD
Vandetanib—SRC—female reproductive system—fallopian tube cancer	0.00518	0.00518	CbGeAlD
Vandetanib—EPHB6—female gonad—fallopian tube cancer	0.00507	0.00507	CbGeAlD
Vandetanib—EPHB6—vagina—fallopian tube cancer	0.00504	0.00504	CbGeAlD
Vandetanib—PDGFRB—endometrium—fallopian tube cancer	0.00498	0.00498	CbGeAlD
Vandetanib—ABL1—uterine cervix—fallopian tube cancer	0.0049	0.0049	CbGeAlD
Vandetanib—YES1—female gonad—fallopian tube cancer	0.0049	0.0049	CbGeAlD
Vandetanib—YES1—vagina—fallopian tube cancer	0.00487	0.00487	CbGeAlD
Vandetanib—STK10—female gonad—fallopian tube cancer	0.00485	0.00485	CbGeAlD
Vandetanib—STK10—vagina—fallopian tube cancer	0.00482	0.00482	CbGeAlD
Vandetanib—KDR—female reproductive system—fallopian tube cancer	0.00476	0.00476	CbGeAlD
Vandetanib—MAP2K5—female reproductive system—fallopian tube cancer	0.00476	0.00476	CbGeAlD
Vandetanib—SRC—female gonad—fallopian tube cancer	0.00471	0.00471	CbGeAlD
Vandetanib—ORM1—endometrium—fallopian tube cancer	0.00467	0.00467	CbGeAlD
Vandetanib—PDGFRB—uterus—fallopian tube cancer	0.00458	0.00458	CbGeAlD
Vandetanib—ABL1—endometrium—fallopian tube cancer	0.00443	0.00443	CbGeAlD
Vandetanib—KDR—female gonad—fallopian tube cancer	0.00433	0.00433	CbGeAlD
Vandetanib—MAP2K5—female gonad—fallopian tube cancer	0.00433	0.00433	CbGeAlD
Vandetanib—MAP2K5—vagina—fallopian tube cancer	0.00431	0.00431	CbGeAlD
Vandetanib—KDR—vagina—fallopian tube cancer	0.00431	0.00431	CbGeAlD
Vandetanib—PDGFRB—female reproductive system—fallopian tube cancer	0.00412	0.00412	CbGeAlD
Vandetanib—ABL1—uterus—fallopian tube cancer	0.00409	0.00409	CbGeAlD
Vandetanib—ORM1—female reproductive system—fallopian tube cancer	0.00387	0.00387	CbGeAlD
Vandetanib—PDGFRB—female gonad—fallopian tube cancer	0.00375	0.00375	CbGeAlD
Vandetanib—ABCC1—uterine cervix—fallopian tube cancer	0.00373	0.00373	CbGeAlD
Vandetanib—PDGFRB—vagina—fallopian tube cancer	0.00373	0.00373	CbGeAlD
Vandetanib—ABL1—female reproductive system—fallopian tube cancer	0.00367	0.00367	CbGeAlD
Vandetanib—ABCC1—endometrium—fallopian tube cancer	0.00338	0.00338	CbGeAlD
Vandetanib—ABL1—female gonad—fallopian tube cancer	0.00334	0.00334	CbGeAlD
Vandetanib—ABL1—vagina—fallopian tube cancer	0.00332	0.00332	CbGeAlD
Vandetanib—ABCC1—uterus—fallopian tube cancer	0.00311	0.00311	CbGeAlD
Vandetanib—ABCG2—uterine cervix—fallopian tube cancer	0.00309	0.00309	CbGeAlD
Vandetanib—ABCG2—endometrium—fallopian tube cancer	0.0028	0.0028	CbGeAlD
Vandetanib—ABCG2—uterus—fallopian tube cancer	0.00258	0.00258	CbGeAlD
Vandetanib—ABCC1—female gonad—fallopian tube cancer	0.00255	0.00255	CbGeAlD
Vandetanib—ABCC1—vagina—fallopian tube cancer	0.00253	0.00253	CbGeAlD
Vandetanib—ABCG2—female gonad—fallopian tube cancer	0.00211	0.00211	CbGeAlD
Vandetanib—ABCG2—vagina—fallopian tube cancer	0.0021	0.0021	CbGeAlD
Vandetanib—CYP3A4—female reproductive system—fallopian tube cancer	0.00161	0.00161	CbGeAlD
